• A A A
Curavac
  • Company
    • About
    • Myasterix
    • Team
    • Board
    • Our Story
  • Science
    • Autoimmune diseases
    • Myasthenia Gravis
    • Scientific publications
  • News
    • Press Release
    • Video Content
    • Published Articles
  • Financing
    • Grants
    • Investments
    • Donations
  • Contact
    • Contact Us
    • Locations
    • Links
Home / Press Release

Press Release

June 2018

THE PHASE 1B OF OUR MYASTHENIA GRAVIS THERAPEUTIC VACCINE DEMONSTRATES AN EXCELLENT SAFETY PROFILE

February 2016

160209 Curavac Plans Ph2 Studies

December 2015

PR_MYASTERIX_2015 December

June 2014

PR_Bio_2014_June

 

Locations

CuraVac Europe S.A.
Avenue de Villefranche, 80
B – 1330 Rixensart
Belgium

 

Contact-us

Copyright 2014 Curavac, All right reserved
inDev